SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

(2021) Evan W. Weber et al.   SCIENCE

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

(2021) Joseph H. Choe et al.   Science Translational Medicine

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

The therapeutic landscape for cells engineered with chimeric antigen receptors

(2020) Matthew MacKay et al.   NATURE BIOTECHNOLOGY

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

(2020) Fabio Nicolini et al.   Frontiers in Oncology

Immunotherapy in Malignant Pleural Mesothelioma

(2020) Cornedine J. de Gooijer et al.   Frontiers in Oncology

Identification of ALPPL2 as a Naive Pluripotent State-Specific Surface Protein Essential for Human Naive Pluripotency Regulation

(2020) Yan Bi et al.   Cell Reports

ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen

(2020) Yang Su et al.   CANCER RESEARCH

Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies

(2020) Ruth Dannenfelser et al.   Cell Systems

Immunotherapy Advances for Epithelial Ovarian Cancer

(2020) Erin G. Hartnett et al.   Cancers

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

(2019) Eric L. Smith et al.   Science Translational Medicine

Chimeric antigen receptor T cell persistence and memory cell formation

(2019) Alexander D McLellan et al.   IMMUNOLOGY AND CELL BIOLOGY

Modulation of chimeric antigen receptor surface expression by a small molecule switch

(2019) Alexandre Juillerat et al.   BMC BIOTECHNOLOGY

Updates on CAR T-cell therapy in B-cell malignancies

(2019) Elad Jacoby et al.   IMMUNOLOGICAL REVIEWS

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

(2019) Katrin Mestermann et al.   Science Translational Medicine

The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies

(2018) Hui Luo et al.   PLoS One

Strategies to Address Chimeric Antigen Receptor Tonic Signaling

(2018) Adam Ajina et al.   MOLECULAR CANCER THERAPEUTICS

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

(2018) Sophie Viaud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma

(2017) Shingo Inaguma et al.   Oncotarget

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

(2017) Takashi Eguchi et al.   Oncotarget

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

(2016) Kole T. Roybal et al.   CELL

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

(2015) Prakash K. Gupta et al.   PLoS Pathogens

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

(2015) M. J. Frigault et al.   Cancer Immunology Research

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

(2013) Petra C Schuberth et al.   Journal of Translational Medicine

Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels

(2012) Evripidis Lanitis et al.   PLoS One

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma

(2009) Scott Bidlingmaier et al.   CANCER RESEARCH

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

(2009) C. Sillaber et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

(2009) Y. Feng et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

(2008) Fei Fei et al.   EXPERIMENTAL HEMATOLOGY

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

(2008) F. An et al.   MOLECULAR CANCER THERAPEUTICS